International Research Collaboration on Drug Abuse and Addiction Research is sponsored by National Institute on Drug Abuse (NIDA). Supports collaborative research projects between U. S.

and European researchers to advance understanding of drug abuse and addiction.

Expired PA-09-021: International Research Collaboration on Drug Abuse and Addiction Research (R21) This notice has expired. Check the NIH Guide for active opportunities and notices. Department of Health and Human Services National Institutes of Health (NIH), ( http://www.

nih. gov ) Components of Participating Organizations Institute on Drug Abuse (NIDA), ( http://www. nida.

nih. gov ) Title : International Research Collaboration on Drug Abuse and Addiction Research (R21) This Funding Opportunity Announcement (FOA) is a reissue of PA-07-310 . Update: The following updates relating to this announcement have been issued: November 29, 2011 - This PA has been reissued as PA-12-041.

September 29, 2010 (NOT-OD-11-007) - NIH to Require Use of Updated Electronic Application Forms in 2011. Adobe B1 forms are required for due dates on or after May 8, 2011. This FOA has been updated to reflect the new requirements from NIH’s Enhancing Peer Review Initiative.

The new requirements are effective for submissions intended for due dates January 25, 2010 and beyond. If submitting an application intended for a due date of January 25, 2010 and beyond, follow the guidance below and be sure to use the Adobe-Forms-B version of the application forms and instructions.

If applying for a due date before January 25, 2010, follow the guidance in the archived version of this FOA and be sure to use the Adobe-Forms-A version of the application forms and instructions. Announcement (PA) Number: PA-09-021 NOTICE: Applications submitted in response to this Funding Opportunity Announcement (FOA) for Federal assistance must be submitted electronically through Grants. gov ( http://www.

grants. gov ) using the SF424 Research and Related (R&R) forms and the SF424 (R&R) Application Guide. MAY NOT BE SUBMITTED IN PAPER FORMAT.

FOA must be read in conjunction with the application guidelines included with this announcement in Grants. gov/Apply for Grants (hereafter called Grants. gov/Apply).

registration process is necessary before submission and applicants are highly encouraged to start the process at least four (4) weeks prior to the grant submission date. See Section IV . Domestic Assistance Number(s) Opening Date: January 16 2009 (Earliest date an application may be submitted to Grants.

gov) Letters of Intent Receipt NOTE: On-time submission requires that applications be successfully submitted to Grants. gov no later than 5:00 p. m.

local time (of the applicant institution/organization). Application Due Date(s): Standard dates apply, please see http://grants1. nih.

gov/grants/funding/submissionschedule. htm AIDS Application Due Date(s ): Standard dates apply, please see http://grants1. nih.

gov/grants/funding/submissionschedule. htm#AIDS . Date(s): Standard dates apply, please see http://grants1.

nih. gov/grants/funding/submissionschedule. htm#reviewandaward Date(s): Standard dates apply, please see http://grants1.

nih. gov/grants/funding/submissionschedule. htm#reviewandaward Anticipated Start Date(s): Standard dates apply, please see http://grants1.

nih. gov/grants/funding/submissionschedule. htm#reviewandaward Information To Be Available Date (URL Activation Date): Not Applicable Expiration Date: January 8, 2012 Purpose .

This Funding Opportunity Announcement (FOA) solicits collaborative research proposals on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery.

Projects must have relevance to the mission of NIDA and where feasible should address NIDAs scientific priority areas. While the priorities will change from year to year, in FY09 priority areas include: linkages between HIV/AIDS and drug abuse, methamphetamine abuse, inhalant abuse, smoking during pregnancy, and drugs and driving.

Mechanism of Support This FOA will use the NIH Exploratory/Developmental (R21) grant mechanism and runs in parallel with FOAs of identical scientific scope, PA-09-020 and PA-09-022 , that solicit applications under the Research Project Grant (R01) and Small Research Grant (R03) award mechanisms, respectively . Funds Available and Anticipated Number of Awards.

Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The total amount awarded and the number of awards will depend upon the mechanism, numbers, quality, duration, and costs of the applications received. and Project Period.

The total project period for an application submitted in response to this funding opportunity may not exceed two years. Direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Application Research Strategy Length: The R21 application Research Plan component of the PHS398 (Item 3) may not exceed 6 pages, including tables, graphs, figures, diagrams, and charts. For information on NIH Exploratory/Developmental Research Grant Award (R21 ). See http://grants.

nih. gov/grants/funding/funding_program. htm Eligible Institutions/Organizations.

Institutions/organizations liste d in Section III, 1. A. are eligible to apply.

Project Directors/Principal Investigators (PDs/PIs). Include Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply of PDs/PIs.

More than one PD/PI (i.e., multiple PDs/PIs), may be designated on the of Applications. Applicants may submit more than one application, provided that each application is scientifically distinct. Resubmissions.

Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Renewals. Exploratory/developmental grant support is for new projects only; renewal (formerly competing continuation) applications will not be accepted.

Materials. See Section IV. 1 for application materials.

All applications, including resubmission, revision and renewal, submitted for due dates January 25, 2010 and beyond, must utilize the current forms and instructions. general information on SF424 (R&R) Application and Electronic Submission, (R&R) Application and Electronic Submission Information: http://grants. nih.

gov/grants/funding/424/index. htm General information on Electronic Submission of Grant Applications: http://era. nih.

gov/ElectronicReceipt/ Hearing Impaired. Telecommunications for the hearing impaired are Part I Overview Information Part II Full Text of Announcement Section I. Funding Opportunity Section II.

Award Information Section III. Eligibility Information 2. Cost Sharing or Matching 3.

Other-Special Eligibility Criteria Section IV. Application and Submission 1. Request Application Information 2.

Content and Form of Application Submission 3. Submission Dates and Times A. Submission, Review, and B.

Submitting an Application Electronically to the NIH C. Application Processing Other Submission Requirements and Information Section V. Application Review Information 2.

Review and Selection Process A. Additional Review Criteria B. Additional Review Considerations C.

Resource Sharing Plan(s) 3. Anticipated Announcement and Award Dates Section VI. Award Administration 2.

Administrative and National Policy Requirements Section VII. Agency Contacts 1. Scientific/Research Contact(s) 2.

Peer Review Contact(s) 3. Financial/Grants Management Contact(s) Section VIII. Other Information - Required Federal Citations Part II - Full Text of Announcement Section I.

Funding Opportunity Description The National Institute on Drug Abuse (NIDA) invites applications for international collaborative research on drug abuse and drug addiction. NIDA is the single largest supporter of research on the causes, consequences, prevention, and treatment of drug addiction in the world.

The mission of the Institute is to bring the power of science to bear on drug abuse and addiction through support and conduct of research across a broad range of disciplines, and ensure rapid and effective dissemination and use of results to improve prevention, treatment, and policy.

The International Program extends the Institute mission internationally through programs that: 1) take advantage of unique opportunities to advance scientific knowledge through research, 2) address the global impact of addiction on public health through activities that build research capacity internationally, and 3) effectively disseminate and share the knowledge gained through NIDA-supported research to scientists, treatment providers, and policy makers around the world.

Activities sponsored and coordinated by the International Program collaborations to conduct research that allow U.S. scientists to take advantage of unique research opportunities. Development of bilateral and multilateral interchanges with other countries and international organizations to share research knowledge for mutual benefit.

Administration of fellowships and professional development activities for U.S. and non-U.S. addiction Co-sponsorship of meetings and symposia with other countries or international organizations. Dissemination of NIDA research and International Program activities to a broad international audience.

Additional information on NIDAs international research program and opportunities for research and research training funding can be found at http://international. drugabuse. gov/home.

html .

In summary, the International Program advances NIDAs mission through fostering international cooperation in drug abuse and addiction research, while integrating NIDAs Divisional research priorities and crosscutting research issues within the frameworks of NIDA, NIH, and HHS health policy and U.S. economic and foreign policy This program announcement is part of NIDAs effort to encourage rigorous collaborative international research and will provide funding for projects conducted in whole or in part outside the U.S. The research must be conducted by U.S. investigators in collaboration with non-U.S.-based investigators.

Either the U.S. or the non-U.S. investigator may serve as principal investigator, but the project must include significant contributions of resources by each participant. Resources may include in kind contributions of personnel, access to study populations, laboratory and other research facilities, etc., as well as funding.

This is a broad call for innovative research and applications are encouraged in all areas of science addressing drug addiction including but not limited to prevention, basic science, epidemiology, treatment and health services.

Of particular interest are projects, that take advantage of a unique set of resources or subject populations which would otherwise be difficult to access The World Health Organization (WHO) reports that more than 15 million people have been diagnosed with drug use disorders, and that injection drug use is present in 136 nations, of which 93 report HIV infection among this population.

Rates of licit drug use are higher: WHO reports that 76. 3 million people have been diagnosed with alcohol use disorders worldwide, and that 1. 1 thousand million people smoke tobacco.

The United Nations Office on Drugs and Crime (UNODC) World Drug Report 2008 estimates that 208 million people, or 4. 9% of the worlds population between 15-64 years of age, use illicit drugs. UNODC statistics from 2006 through 2007 demonstrate that cannabis was the most frequently used illicit drug (165.

6 million users), followed by amphetamine-type stimulants (33. 7 million users), opiates (16. 5 million users), and cocaine (16 million users).

UNODC reported that opiate abuse was the most common reason for seeking drug treatment globally during 2006-2007, particularly in Asia and Europe, where it accounts for more than 60% of the demand for treatment. Nearly one-third (32. 6%) of the demand for drug treatment in Oceania is attributable to opiate abuse.

Although cocaine abuse has declined dramatically in North America (UNODC reports that the proportion of the U.S. workforce testing positive for cocaine has declined by 36% since 1998) it still accounts for 31. 2% of treatment demand there, and for 54% of treatment demand in South America. In Africa (63.

6%) and Oceania (47. 3%), cannabis abuse was the most frequently cited reason for seeking drug treatment. Cannabis abuse accounted for nearly one-third of the demand for treatment in North (35.

3%) and South (30. 8%) America. Although demand for treatment for amphetamine-type stimulant (ATS) abuse (including methamphetamine and ecstasy) is highest in Asia (19.

1%), UNODC notes that the 33. 7 million global ATS users outnumber the combined total of all heroin and cocaine users. Drug Report 2008 calls public health the first principle of drug control and says that drug dependence is an illness that should be treated like any other.

It adds that more resources are needed to prevent people from taking drugs, to treat those who are dependent, and to reduce the adverse health and social consequences of drug abuse. NIDA was one of the first drug abuse research agencies to adopt that public health approach as the crises of drug abuse and addiction intensified during the late 20th Century.

NIDA formally created the International Program in 1990 because the Institute recognized that multinational cooperation was urgently required to effectively address the pandemic.

The science-based information generated by NIDA researchers and the International Program alumni contributes to international efforts to develop, adopt, and evaluate government policies, prevention programs, and treatment protocols that effectively address drug abuse and its consequences. epidemics generally follows a discernable pattern.

Frequently, countries with no history of drug use become transit, then trafficking, and then consuming countries. This rapid spread of drug abuse has called attention to the need for research cooperation involving all countries. The capacity to respond varies greatly among nations, and treatment needs remain unmet around the globe.

Some countries have a research infrastructure and are conducting drug abuse studies; others have a more limited research base and lack resources to create the necessary infrastructure. Of central importance is the role of illicit drugs in the spread of HIV. The number of countries reporting both injection drug use (IDU) and related HIV infection has increased to 127.

In addition, countries that report to the UN drug monitoring system are reporting general increases in illicit drug use and related health consequences. High-tech communications, continuous marketing innovations, and increased transport between countries ensure rapid spread of drug use and increasingly rapid transmission of infectious diseases.

Significantly, increases in IDU are frequently signaled by increases in sexually transmitted diseases and accompanied by increases in HIV, hepatitis, tuberculosis, and other infectious diseases.

These problems have become a major public health issue in many countries, especially in areas with economic of Research Focus include, but are not limited to: This program announcement is open to researchers in all areas of NIDA-supported science, including basic laboratory studies, clinical studies, epidemiological studies, community-based studies, and services research.

The intent of this program is to stimulate state-of-the-science collaborative research between investigators from domestic U.S. institutions and researchers in other countries.

Funds are being made available to take advantage of new opportunities to establish collaborative relationships with scientists conducting research or with a potential to conduct research in other countries as well as to support new research projects from established collaborators.

NIDA is also very interested in establishing relationships with science-funding organizations in other countries, and so programmatic priority funding will be given to projects that are collaboratively funded by an agency of the foreign country.

Research priority areas have been identified that are international in scope, are associated with substantial detrimental health consequences, and for which an international collaborative research may provide a unique opportunity to expand our knowledge and ability to effectively respond.

While this call is meant to be very broad and inclusive, the following areas of research are current priority areas: HIV/AIDS and drug abuse drug abuse continues to be an important factor in the continued spread of HIV in many regions.

Studies are needed to develop and implement epidemiological studies, prevention, and treatment protocols to better assess the role of drugs in HIV transmission and to ameliorate the consequences of both drug abuse and HIV/AIDS. Methamphetamine methamphetamine abuse is a growing problem in the United States and around the world.

Studies are encouraged to assess the nature and extent of methamphetamine abuse, its long term sequela, and prevention and continue to be an under-recognized public health problem in many countries.

Studies are encouraged to improve epidemiological data on the nature and extent of abuse, to develop and implement effective prevention programs, to better understand the neurobiological impacts of these agents, and to increase public awareness of their impact.

studies are encouraged to increase our knowledge of the prenatal impact of smoking and the effects of early exposure to tobacco in young people and adolescents on development of addiction and other diseases and on Drugged driving studies are encouraged to develop and utilize accurate drug testing technologies to assess the prevalence of driving under the influence of drugs, the role of drugs in accidents, and to assess the costs and benefits of laws and other programs to reduce the incidence and impact of drugged driving.

areas of interest include, but are not limited to: Development of surveillance systems to track and respond to emerging drug epidemics, identifying abuse of novel drugs; optimal ways to respond to emerging epidemics and consider the range of linked services (e.g., drug treatment, primary care, health, social, recreational, educational, juvenile justice) for defined populations in various cultural settings; Optimal ways to respond to emerging epidemics and evaluate the impact of a range of linked services (e.g., drug treatment, primary care, health, social, recreational, educational, juvenile justice) for defined populations in various cultural Research on systems or practices that enhance technology transfer and investigate how to integrate research findings into practice in a timely manner across different cultures; this may include a new research methodology or approach (e.g., valid/reliable cross-cultural measure of quality of care), rapid testing of drug use for screening drivers, or physician based education on smoking cessation treatments for pregnant women); Research to adapt and test innovative prevention interventions or treatments; test replicability of established prevention/treatment programs, identify key intervention components that impede or account for success in the adaptation process; culturally related barriers and facilitators to implementation; and processes and mechanisms that increase program fidelity and the potential Identification of factors that underlie treatment-seeking behavior in different countries and address the unmet need for treatment (for example, outreach interventions aimed at children at highest risk for inhalant abuse); Secondary data analysis of existing data sources and when available comparison of international data; Research that takes advantage of particular population characteristics (e.g., genotype, drug use patterns, cultural sanctions) to isolate and study variables underlying risk for drug addiction and impact of use; Basic research in behavior, cognition and neurobiology that capitalizes on unique opportunities in populations of abusers that are characterized by different patterns of abuse than is typically seen in the United States; for example, select groups that use unusual routes of administration, drug combinations, or whose abuse is directed at only one particular drug of abuse rather than the polydrug abuse that typifies users and addicts in the United States; And preclinical and other human or animal laboratory studies relevant to the study of addiction and addictive processes.

For example, basic research that expands our knowledge of the impact of drug use on brain development among children and adolescents, as well as knowledge regarding gene and environment In summary, the overall purpose of this program announcement is to support state-of-the-science collaborative research between investigators from domestic U.S. institutions and researchers in other countries.

Priority will be given to projects that address linkages between HIV/AIDS and drug abuse, methamphetamine abuse, inhalant abuse, smoking during pregnancy, and drugged driving; as well as research projects that are responsive to NIDAs Divisional research priorities and crosscutting research issues within the frameworks of NIDA.

Counseling and Testing Policy for the National Institute on Drug Abuse : In light of recent significant advances in rapid testing for HIV and in effective treatments for HIV, NIDA has revised its 2001 policy on HIV counseling and testing.

NIDA-funded researchers are strongly encouraged to provide and/or refer research subjects to HIV risk reduction education and education about the benefits of HIV treatment, counseling and testing, referral to treatment, and other appropriate interventions to prevent acquisition and transmission of HIV. This policy applies to all NIDA funded research conducted domestically or internationally. For more information see http://grants.

nih. gov/grants/guide/notice-files/NOT-DA-07-013. html .

Advisory Council on Drug Abuse Recommended Guidelines for the Administration of Drugs to Human Su bjects : The National Advisory Council on Drug Abuse (NACDA) recognizes the importance of research involving the administration of drugs with abuse potential, and dependence or addiction liability, to human subjects.

Potential applicants are encouraged to obtain and review these recommendations of Council before submitting an application that will administer compounds to human subjects. The guidelines are available on NIDA's Web site at http://www. nida.

nih. gov/about/organization/nacda/CouncilStatement. html .

Website for Consultation and Collaboration has established a web-based Networking Project (NNP) to encourage investigators to collaborate with other scientists to gain access to specialized expertise, unique research resources, diverse populations, or geographic locations not otherwise available. For applicants interested in identifying potential collaborators, the NNP website is available at http://nnp. drugabuse.

gov, as a source of information on the mission, focus, and leadership of NIDAs research networks. The website features an interactive map with more than 300 local network sites, a directory of close to 400 addiction researchers and practitioners, and the extensive resources of 14 NIDA-supported research networks located across the country.

If appropriate for the proposed research, NIDA encourages grant applicants to use the resources of the NNP and make reference in the grant application when they are utilized. The evolution and vitality of the biomedical sciences require a constant infusion of new ideas, techniques, and points of view. These may differ substantially from current thinking or practice and may not yet be supported by substantial preliminary data.

By using the R21 mechanism, the NIH seeks to foster the introduction of novel scientific ideas, model systems, tools, agents, targets, and technologies that have the potential to substantially advance biomedical research. The R21 mechanism is intended to encourage new exploratory and developmental research projects.

For example, such projects could assess the feasibility of a novel area of investigation or a new experimental system that has the potential to enhance health-related research. Another example could include the unique and innovative use of an existing methodology to explore a new scientific area.

These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Applications for R21 awards should describe projects distinct from those supported through the traditional R01 mechanism.

For example, long-term projects, or projects designed to increase knowledge in a well-established area, will not be considered for R21 awards. Applications submitted under this mechanism should be exploratory and novel. These studies should break new ground or extend previous discoveries toward new directions or applications.

Projects of limited cost or scope that use widely accepted approaches and methods within well established fields are better suited for the R03 small grant mechanism. Information on the R03 program can be found at http://grants. nih.

gov/grants/funding/r03. htm . See Section VIII, Other Information - Required Federal Citations , for policies related This FOA will use the NIH Exploratory/Developmental Research Grant (R21) award mechanism .

The Project Director/Principal Investigator (PD/PI) will be solely responsible for planning, directing, and executing the proposed project. Just-in-Time information concepts see SF424 (R&R) Application Guide ) . It also uses the modular as well as the non-modular budget formats (see the Modular Applications and Awards section of the NIH Grants Policy Statement .

Specifically, if you are submitting an application with direct costs in each year of $250,000 or less (excluding consortium Facilities and Administrative [F&A] costs), use the PHS398 Modular Budget component provided in the SF424 (R&R) Application Package and SF424 (R&R) Application Guide (see specifically Section 3. 4, Modular Budget Component, of the Application Guide).

All foreign applicants must complete and submit budget requests using the Research & Related Budget component. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.

Although the financial plans of the Institutes and Centers (ICs) provide support for this program, awards pursuant to this funding opportunity are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The total project period for an application submitted in response to this funding opportunity may not exceed 2 years.

Although the size of award may vary with the scope of research proposed, it is expected that applications will stay within the budgetary guidelines for an exploratory/developmental project; direct costs are limited to $275,000 over an R21 two-year period, with no more than $200,000 in direct costs allowed in any single year.

Applicants may request direct costs in $25,000 modules, up to the total direct costs limitation of $275,000 for the combined two-year award period. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made F&A costs requested by consortium participants are not included in the direct cost limitation. See NOT-OD-05-004 , November 2, III.

Eligibility Information The following organizations/institutions Controlled Institutions of Higher Education Institutions of Higher Education Historically Black Colleges Tribally Controlled Colleges and Universities (TCCUs) Alaska Native and Native Hawaiian Serving with 501(c)(3) IRS Status (Other than Institutions of Higher Education) without 501(c)(3) IRS Status (Other than Institutions of Higher Education) Organizations (Other than Small Businesses) American Tribal Governments (Federally Recognized) American Tribally Designated Organizations Housing Authorities/Indian Housing Authorities U.S. Territory or Possession American Tribal Governments (Other than Federally Recognized) Non-domestic (non-U.S.) Entities (Foreign Organizations) Eligible Agencies of the Federal Government Faith-based or Community-based Organizations.

individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the PD/PI is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

than one PD/PI (i.e., multiple PDs/PIs), may be designated on the application for projects that require a team science approach and therefore clearly do not fit the single-PD/PI model. Additional information on the implementation plans and policies and procedures to formally allow more than one PD/PI on individual research projects is available at http://grants. nih.

gov/grants/multi_pi . All PDs/PIs must be registered in the NIH electronic Research Administration (eRA) Commons prior to the submission of the application (see http://era. nih.

gov/ElectronicReceipt/preparing. htm for instructions). decision of whether to apply for a grant with a single PD/PI or multiple PDs/PIs grant is the responsibility of the investigators and applicant organizations and should be determined by the scientific goals of the project.

Applications for grants with multiple PDs/PIs will require additional information, as outlined in the instructions below. When considering the multiple PD/PI option, please be aware that the structure and governance of the PD/PI leadership team as well as the knowledge, skills and experience of the individual PDs/PIs will be factored into the assessment of the overall scientific merit of the application.

Multiple PDs/PIs on a project share the authority and responsibility for leading and directing the project, intellectually and logistically. Each PD/PI is responsible and accountable to the grantee organization, or, as appropriate, to a collaborating organization, for the proper conduct of the project or program, including the submission of required reports. For further information on multiple PDs/PIs, please see http://grants.

nih. gov/grants/multi_pi . does not require cost sharing as defined in the current NIH Grants Policy Statement .

may submit a resubmission application, but such application must include an Introduction addressing issues raised in the previous critique (Summary may not submit a renewal application. Applicants may submit more than one application, provided that each application is scientifically distinct. Section IV.

Application and Submission Information download a SF424 (R&R) Application Package and SF424 (R&R) Application Guide for completing the SF424 (R&R) forms for this FOA, use the Apply for Grant Electronically button in this FOA or link to http://www. grants. gov/Apply/ and follow the directions provided on that Web site.

A one-time registration is required for institutions/organizations at both: Grants. gov ( http://www. grants.

gov/applicants/get_registered. jsp ) eRA Commons ( http://era. nih.

gov/ElectronicReceipt/preparing. htm ) PDs/PIs should work with their institutions/organizations to make sure they are registered in the NIH eRA Commons. additional separate actions are required before an applicant can submit an electronic application, as follows: 1) Organizational/Institutional Registration in Grants.

gov/Get Registered . Your organization will need to obtain a Data Universal Number System (DUNS) number and register with the Central Contractor Registration (CCR) as part of the Grants. gov registration process.

If your organization does not have a Taxpayer Identification Number (TIN) or Employer Identification Number (EIN), allow for extra time. A valid TIN or EIN is necessary for CCR registration. The CCR also validates the EIN against Internal Revenue Service records, a step that will take an additional one to two business days.

Direct questions regarding Grants. gov registration to: Grants. gov Customer Support Business Hours: M-F 7:00 a.

m. - 9:00 p. m.

Eastern Time 2) Organizational/Institutional Registration in the eRA Commons To find out if an organization is already Commons-registered, see Organizations Registered in NIH eRA Commons. Direct questions regarding the Commons registration to: Phone: 301-402-7469 or 866-504-9552 (Toll Free) Business hours M-F 7:00 a. m.

8:00 p. m. Eastern Time Director/Principal Investigator (PD/PI) Registration in the NIH eRA Commons: Refer to the NIH eRA Commons System (COM) The individual(s) designated as PDs/PIs on the application must be registered also in the NIH eRA Commons.

In the case of multiple PDs/PIs, all PDs/PIs must be registered and be assigned the PI role in the eRA Commons prior to the submission of the application. Each PD/PI must hold a PD/PI account in the Commons.

Applicants should not share a Commons account for both an Authorized Organization Representative/Signing Official (AOR/SO) role and a PD/PI role; however, if they have both a PD/PI role and an NIH Internet Assisted Review (IAR) role, both roles should exist under one Commons account. When multiple PDs/PIs are proposed, all PDs/PIs at the applicant organization must be affiliated with that organization.

PDs/PIs located at another institution need not be affiliated with the applicant organization, but must be affiliated with their own organization to be able This registration/affiliation must be done by the AOR/SO or his/her designee who is already registered in the Commons. Both the PD/PI and AOR/SO need separate accounts in the NIH eRA Commons since both are authorized to view the application image.

also an NIH peer-reviewer with an Individual DUNS and CCR registration, that particular DUNS number and CCR registration are for the individual reviewer only. These are different than any DUNS number and CCR registration used by an applicant organization.

Individual DUNS and CCR registration should be used only for the purposes of personal reimbursement and should not be used on any grant applications submitted to the Federal Government. Several of the steps of the registration process could take four weeks or more. Therefore, applicants should immediately check with their business official to determine whether their organization/institution is already registered in both Grants.

gov and the Commons . The NIH will accept electronic applications only from organizations that have completed all 1. Request Application Information download the SF424 (R&R) application forms and SF424 (R&R) Application Guide for this FOA through Grants.

gov/Apply . Only the forms package directly attached to a specific FOA can be used. You will not be able to use any other SF424 (R&R) forms